[1] |
WANG Chunting, CHEN Yafei.
Considerations for Revision of Safety Information in the Post-Marketing Instructions of Chemical Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 776-779.
|
[2] |
ZHONG Ling, ZENG Huiyan, YUAN Xin, WANG Yingyan.
Adverse Event Signals of Liraglutide and Semaglutide Based on the FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 305-312.
|
[3] |
ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi.
Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192.
|
[4] |
WANG Dan, DONG Duo, TIAN Chunhua.
Course of development of pharmocovigilance systems in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
|
[5] |
HAN Li, CHEN Li, CHEN Qian, XIAO Hongtao.
Signal detection of adverse reaction of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 440-446.
|
[6] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|
[7] |
XIONG Weiyi, REN Jingtian.
Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
|
[8] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[9] |
PAN Zhemin, XU Sheng, ZHENG Yi, CHEN Chenxin, LIU Yongmei, ZHANG Pengpeng, YE Xiaofei, HE Jia.
Comparison of likelihood ratio tests in post-marketing safety surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 655-660.
|
[10] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
[11] |
LEI Chao, QIAO Meng, CHEN Zijia, ZHANG Qiang, XIE Yanming, WANG Zhifei.
Revision of safety information in instructions of traditional Chinese patent medicines and simple preparations
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1396-1400.
|
[12] |
JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang.
Evaluation index system of MAH pharmacovigilance work
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
|
[13] |
SU Xinxin, ZHAO Xiaoxiao, XIE Yanming.
Real-world analysis of combined administration of elemene emulsion injection in patients with liver cancer
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 929-934.
|
[14] |
HUANG Yanli, XIE Yanming, WANG Lianxin, SUN Linxi, LIU Huan, ZHUANG Yunni.
Clinical applications of Ciwujia injection in elderly patients in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 935-939.
|
[15] |
ZHANG Hongwei, LI Yuanyuan, XIE Yanming, MA Xiaochang, WANG Lianxin, WEI Ruili, SUN Linxi, XU Hongyan, ZHUANG Yan.
The drug combination of Danshen Ligustrazine injection in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 851-856.
|